Navigation Links
Electrophysiology Procedures for Atrial Fibrillation Treatment to Grow Over 25% Annually Over the Next Five Years

Growth will be driven by an increasing physician acceptance of

electrophysiology ablation as an effective treatment for atrial

fibrillation, according to Millennium Research Group

WALTHAM, Mass., March 20 /PRNewswire/ -- According to Millennium Research Group's Global Markets for Atrial Fibrillation (AF) Treatment Devices 2008 report, over 32,000 electrophysiology (EP) procedures were performed for the treatment of AF in the US in 2007. AF EP procedure volumes will increase at a compound annual growth rate of over 25% from 2008 to 2012.

Growth in procedure volumes will be driven by the increasing physician acceptance of EP ablation as a viable and effective treatment for AF. Over the next several years, these procedures will be used more often over medical therapy than in the past. The introduction of new technology will also support greater procedure volumes through 2012; these new devices will enable physicians to increase the safety, efficiency, and efficacy of EP ablation catheter procedures. By 2012, over 109,000 EP procedures will be performed to treat AF in the US.

"The patient pool that hasn't been treated in this market is huge and growing," says Andrew Wong, Analyst at Millennium Research Group. "Almost 3 million people have atrial fibrillation in the US, but currently only about 100,000 are being treated annually."

The Global Markets for Atrial Fibrillation Treatment Devices 2008 report includes coverage of the AF EP, cardiac rhythm management, and surgical ablation device markets. This report provides coverage of US, Europe, and Japan and all key industry competitors, including Biosense Webster, Boston Scientific, Medtronic, and St. Jude Medical.

About Atrial Fibrillation

AF is a type of cardiac arrhythmia. In AF, the atria of the heart are stimulated by abnormal electrical impulses from the sinoatrial node and malfunctioning atrial tissue, resulting in an irregular and disorganized heart beat. AF can lead to heart failure and has been recognized as a major risk factor for stroke. Increased age and unhealthy lifestyle choices are risk factors in developing AF.

About Millennium Research Group

Millennium Research Group (, a Decision Resources, Inc. company (, is the global authority on medical technology market intelligence and a leading provider of strategic information to the health care sector. Focused solely on the medical device, pharmaceutical, and biotechnology industries, the company provides its clients with the benefits of its specialized industry expertise through published reports and customized consulting services.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Amy Krohn

Millennium Research Group

416-364-7776 x101

SOURCE Millennium Research Group
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Signalife Presence at XIII World Congress on Cardiac Pacing and Electrophysiology
2. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
3. Stereotaxis Niobe System Used to Perform More Than 10,000 Procedures Worldwide
4. Hyaluronic Acid Knee Procedures Grow 38% from Q3 2006 to Q3 2007
5. Anesiva Announces Submission of Supplemental New Drug Application for Zingo(TM) to Reduce Pain Associated With Needle Insertion Procedures in Adults
6. CryoCor to Highlight Products at 13th Annual International Boston Atrial Fibrillation Symposium
7. AtriCure Announces Initiation of the ABLATE Pivotal Trial to Evaluate the Isolator Synergy(TM) Bipolar Ablation System to Treat Atrial Fibrillation
8. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
9. Johns Hopkins to add Elekta Synergy S(R) to Cancer Treatment Lineup
10. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
11. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
Post Your Comments:
(Date:11/30/2015)... and PETACH TIKVAH, Israel , Nov. ... BCLI ), a leading developer of adult stem cell ... Brainstorm Cell Therapeutics Ltd., has been awarded an additional grant ... of the Chief Scientist (OCS). This grant, the second this ... 2015 activities to approximately $1.8 million (approximately NIS7 million).  ...
(Date:11/27/2015)... , Nov. 27, 2015 /PRNewswire/--  Mallinckrodt plc ... announced today that it has closed the sale of ... to Guerbet (GBT- NYSE Euronext) in a transaction valued ... four manufacturing facilities and a total of approximately 1,000 ... the St. Louis area. This ...
(Date:11/27/2015)... November 27, 2015 ... popularity of companion diagnostics is one of ... market with pharmaceutical companies and diagnostic manufacturers ... tests. . --> ... report on global cancer biomarkers market spread ...
(Date:11/26/2015)... , November 26, 2015 ... device company specializing in imaging technologies, announced today that it ... as part of the Horizon 2020 European Union Framework Programme ... a large-scale clinical trial in breast cancer. , ... , --> --> The ...
Breaking Biology Technology:
(Date:10/29/2015)... Connecticut , October 29, 2015 ... a biometric authentication company focused on the growing ... smart wallet announces that StackCommerce, a leading marketplace ... be featuring the Wocket® smart wallet on StackSocial ... NXTD ) ("NXT-ID" or the "Company"), a biometric ...
(Date:10/27/2015)... October 27, 2015 Munich, ... Gaze Mapping technology (ASGM) automatically maps data from mobile ... Glasses , so that they can be quantitatively ... Munich, Germany , October 28-29, 2015. ... data from mobile eye tracking videos created with ...
(Date:10/26/2015)... LAS VEGAS , Oct. 26, 2015 ... an innovator in modern authentication and a founding member ... launch of its latest version of the Nok Nok™ ... to use standards-based authentication that supports existing and emerging ... Suite is ideal for organizations deploying customer-facing applications that ...
Breaking Biology News(10 mins):